FeesSafety
Pluang+

Chicago Atlantic reports Q3 2026 distributable earnings of $0.49 per share amid challenging market conditions

Company Fundamentals
10 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Neutral
Chicago Atlantic reports Q3 2026 distributable earnings of $0.49 per share amid challenging market conditions

Chicago Atlantic Real Estate Finance, Inc. announced distributable earnings of $0.49 per diluted share for Q3 2026 despite a tough economic and regulatory environment. The company’s cannabis-related loan portfolio decreased slightly but maintains strong credit fundamentals. A pending merger with Chicago Atlantic BDC, Inc. is expected to close in 2027, potentially reshaping the company’s structure. The company plans to maintain a dividend payout ratio of 90-100% for 2026, reflecting confidence in its long-term strategy and underwriting discipline.

Chicago Atlantic Real Estate Finance's Q3 2026 results provide context for readers. For those following Real Estate sector stocks, 24 of 47 priced US stocks rose and 16 fell on Pluang. Notable movers include Extra Space Storage at USD 159.51 with 17% sell and 83% buy activity, ARMOUR Residential REIT at USD 12.82 with 9% sell and 91% buy, and CBRE Group at USD 138.69 with 3% sell and 97% buy, as of Nov 10, 2026 17:41 WIB.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
59 minutes ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
59 minutes ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
59 minutes ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
59 minutes ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App